Comparison of Therapeutic Effect of Apheresis Platelets and Buffy Coat-Derived Platelet Concentrates.

IF 0.7 4区医学 Q4 MEDICAL LABORATORY TECHNOLOGY

Clinical laboratory Pub Date : 2024-08-01 DOI:10.7754/Clin.Lab.2024.231149

Zhaolong Wang, Xiaoling Chen, Yangmin Zhang, Hairong Lu, Lifen Ren

{"title":"Comparison of Therapeutic Effect of Apheresis Platelets and Buffy Coat-Derived Platelet Concentrates.","authors":"Zhaolong Wang, Xiaoling Chen, Yangmin Zhang, Hairong Lu, Lifen Ren","doi":"10.7754/Clin.Lab.2024.231149","DOIUrl":null,"url":null,"abstract":"Background: The study aimed to investigate the difference in clinical efficacy between apheresis platelets and buffy coat-derived platelet concentrates infusion in patients with hematological diseases.Methods: A total of 218 patients with hematological diseases were enrolled in Xi'an Central Hospital, from January 2023 to October 2023, and randomly divided into two groups: 109 patients were treated with apheresis platelet transfusion (AP group) and 109 patients with buffy coat derived platelet concentrates (BC-PC group). Platelet counts were measured before and 24 hours after transfusion, and the corrected platelet ascending number (CCI) and platelet recovery rate (PPR) were calculated. The clinical efficacy and blood transfusion reaction were observed.Results: After 24 hours of platelet transfusion, there was no significant difference in the platelet count between the AP and BC-PC groups (p > 0.05). However, CCI and PPR significantly differed between the two groups (p < 0.05). Moreover, the incidence of transfusion reaction in the AP group was significantly lower than in the BC-PC group.Conclusions: The clinical efficacy of buffy coat-derived platelet concentrates is lower than that of apheresis platelets, but it can also improve the patient's condition and quality of life. Therefore, clinicians could rationally use BC-PC, according to the actual situation of the patients.","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"70 8","pages":""},"PeriodicalIF":0.7000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical laboratory","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7754/Clin.Lab.2024.231149","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The study aimed to investigate the difference in clinical efficacy between apheresis platelets and buffy coat-derived platelet concentrates infusion in patients with hematological diseases.

Methods: A total of 218 patients with hematological diseases were enrolled in Xi'an Central Hospital, from January 2023 to October 2023, and randomly divided into two groups: 109 patients were treated with apheresis platelet transfusion (AP group) and 109 patients with buffy coat derived platelet concentrates (BC-PC group). Platelet counts were measured before and 24 hours after transfusion, and the corrected platelet ascending number (CCI) and platelet recovery rate (PPR) were calculated. The clinical efficacy and blood transfusion reaction were observed.

Results: After 24 hours of platelet transfusion, there was no significant difference in the platelet count between the AP and BC-PC groups (p > 0.05). However, CCI and PPR significantly differed between the two groups (p < 0.05). Moreover, the incidence of transfusion reaction in the AP group was significantly lower than in the BC-PC group.

Conclusions: The clinical efficacy of buffy coat-derived platelet concentrates is lower than that of apheresis platelets, but it can also improve the patient's condition and quality of life. Therefore, clinicians could rationally use BC-PC, according to the actual situation of the patients.

查看原文本刊更多论文

比较凝血酶原血小板和巴菲衣衍生血小板浓缩物的治疗效果

背景：该研究旨在探讨血液病患者输注无细胞血小板和水衣源性血小板浓缩物的临床疗效差异：本研究旨在探讨血液病患者输注无细胞血小板与输注水衣源性血小板浓缩液的临床疗效差异：2023年1月至2023年10月，西安市中心医院共收治218例血液病患者，随机分为两组：109例患者输注无细胞血小板（AP组），109例患者输注水衣血小板浓缩液（BC-PC组）。分别在输血前和输血后 24 小时测量血小板计数，并计算校正血小板升高数（CCI）和血小板恢复率（PPR）。观察临床疗效和输血反应：结果：输注血小板 24 小时后，AP 组和 BC-PC 组的血小板计数无明显差异（P > 0.05）。但是，两组之间的 CCI 和 PPR 有明显差异（P < 0.05）。此外，AP组的输血反应发生率明显低于BC-PC组：结论：水衣源血小板浓缩物的临床疗效低于无细胞血小板，但也能改善患者的病情和生活质量。因此，临床医生可根据患者的实际情况合理使用 BC-PC。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical laboratory 医学-医学实验技术

CiteScore

1.50

自引率

0.00%

发文量

494

审稿时长

3 months

期刊介绍： Clinical Laboratory is an international fully peer-reviewed journal covering all aspects of laboratory medicine and transfusion medicine. In addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies. The journal publishes original articles, review articles, posters, short reports, case studies and letters to the editor dealing with 1) the scientific background, implementation and diagnostic significance of laboratory methods employed in hospitals, blood banks and physicians'' offices and with 2) scientific, administrative and clinical aspects of transfusion medicine and 3) in addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies.